nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA12—Hydrochlorothiazide—nephrolithiasis	0.169	0.216	CbGbCtD
Nilotinib—CA9—Hydrochlorothiazide—nephrolithiasis	0.169	0.216	CbGbCtD
Nilotinib—CA1—Hydrochlorothiazide—nephrolithiasis	0.158	0.202	CbGbCtD
Nilotinib—CA4—Hydrochlorothiazide—nephrolithiasis	0.148	0.19	CbGbCtD
Nilotinib—CA2—Hydrochlorothiazide—nephrolithiasis	0.136	0.175	CbGbCtD
Nilotinib—CA2—collecting duct of renal tubule—nephrolithiasis	0.00554	0.0835	CbGeAlD
Nilotinib—Localised oedema—Hydrochlorothiazide—nephrolithiasis	0.00517	0.0483	CcSEcCtD
Nilotinib—Cardiac murmur—Hydrochlorothiazide—nephrolithiasis	0.00421	0.0394	CcSEcCtD
Nilotinib—UGT1A1—urine—nephrolithiasis	0.00398	0.06	CbGeAlD
Nilotinib—Electrolyte imbalance—Hydrochlorothiazide—nephrolithiasis	0.00313	0.0292	CcSEcCtD
Nilotinib—Joint swelling—Hydrochlorothiazide—nephrolithiasis	0.00266	0.0249	CcSEcCtD
Nilotinib—FRK—renal system—nephrolithiasis	0.00257	0.0386	CbGeAlD
Nilotinib—CDC42BPB—renal system—nephrolithiasis	0.00216	0.0326	CbGeAlD
Nilotinib—CDC42BPB—cortex of kidney—nephrolithiasis	0.00204	0.0307	CbGeAlD
Nilotinib—MAPK8—renal system—nephrolithiasis	0.00196	0.0295	CbGeAlD
Nilotinib—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0019	0.0177	CcSEcCtD
Nilotinib—MAPK8—kidney—nephrolithiasis	0.00189	0.0285	CbGeAlD
Nilotinib—MAPK8—cortex of kidney—nephrolithiasis	0.00184	0.0277	CbGeAlD
Nilotinib—Hyperlipidaemia—Hydrochlorothiazide—nephrolithiasis	0.00181	0.0169	CcSEcCtD
Nilotinib—CYP2C9—urine—nephrolithiasis	0.00167	0.0252	CbGeAlD
Nilotinib—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.00166	0.0155	CcSEcCtD
Nilotinib—Gamma-glutamyltransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00159	0.0148	CcSEcCtD
Nilotinib—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.00146	0.0136	CcSEcCtD
Nilotinib—CA7—renal system—nephrolithiasis	0.00145	0.0219	CbGeAlD
Nilotinib—Gastrooesophageal reflux disease—Hydrochlorothiazide—nephrolithiasis	0.00145	0.0135	CcSEcCtD
Nilotinib—Nocturia—Hydrochlorothiazide—nephrolithiasis	0.00141	0.0132	CcSEcCtD
Nilotinib—Hyperuricaemia—Hydrochlorothiazide—nephrolithiasis	0.00141	0.0132	CcSEcCtD
Nilotinib—CA7—kidney—nephrolithiasis	0.0014	0.0211	CbGeAlD
Nilotinib—Gout—Hydrochlorothiazide—nephrolithiasis	0.0014	0.0131	CcSEcCtD
Nilotinib—Hypercholesterolaemia—Hydrochlorothiazide—nephrolithiasis	0.00138	0.0129	CcSEcCtD
Nilotinib—Bone pain—Hydrochlorothiazide—nephrolithiasis	0.00136	0.0127	CcSEcCtD
Nilotinib—Blood uric acid increased—Hydrochlorothiazide—nephrolithiasis	0.00133	0.0124	CcSEcCtD
Nilotinib—Musculoskeletal pain—Hydrochlorothiazide—nephrolithiasis	0.00132	0.0124	CcSEcCtD
Nilotinib—EPHB4—nephron tubule—nephrolithiasis	0.0013	0.0195	CbGeAlD
Nilotinib—Hyperkalaemia—Hydrochlorothiazide—nephrolithiasis	0.00128	0.012	CcSEcCtD
Nilotinib—CYP3A4—urine—nephrolithiasis	0.00128	0.0192	CbGeAlD
Nilotinib—EPHA2—nephron tubule—nephrolithiasis	0.00127	0.0191	CbGeAlD
Nilotinib—Wheezing—Hydrochlorothiazide—nephrolithiasis	0.00127	0.0119	CcSEcCtD
Nilotinib—CYP2D6—urine—nephrolithiasis	0.00126	0.0189	CbGeAlD
Nilotinib—MAPK14—renal system—nephrolithiasis	0.00124	0.0187	CbGeAlD
Nilotinib—Blood urea increased—Hydrochlorothiazide—nephrolithiasis	0.00123	0.0115	CcSEcCtD
Nilotinib—MAPK14—kidney—nephrolithiasis	0.0012	0.0181	CbGeAlD
Nilotinib—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.00118	0.011	CcSEcCtD
Nilotinib—EPHB4—renal system—nephrolithiasis	0.00118	0.0177	CbGeAlD
Nilotinib—Pulmonary oedema—Hydrochlorothiazide—nephrolithiasis	0.00116	0.0109	CcSEcCtD
Nilotinib—EPHB4—kidney—nephrolithiasis	0.00114	0.0172	CbGeAlD
Nilotinib—TEK—renal system—nephrolithiasis	0.00113	0.017	CbGeAlD
Nilotinib—EPHB4—cortex of kidney—nephrolithiasis	0.00111	0.0167	CbGeAlD
Nilotinib—TEK—kidney—nephrolithiasis	0.00109	0.0164	CbGeAlD
Nilotinib—Diabetes mellitus—Hydrochlorothiazide—nephrolithiasis	0.00109	0.0102	CcSEcCtD
Nilotinib—Photosensitivity—Hydrochlorothiazide—nephrolithiasis	0.00108	0.0101	CcSEcCtD
Nilotinib—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00107	0.00999	CcSEcCtD
Nilotinib—TEK—cortex of kidney—nephrolithiasis	0.00106	0.016	CbGeAlD
Nilotinib—PDGFRA—renal system—nephrolithiasis	0.00102	0.0154	CbGeAlD
Nilotinib—EPHB6—cortex of kidney—nephrolithiasis	0.00101	0.0153	CbGeAlD
Nilotinib—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.00101	0.00943	CcSEcCtD
Nilotinib—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.001	0.00935	CcSEcCtD
Nilotinib—Arthritis—Hydrochlorothiazide—nephrolithiasis	0.000975	0.00911	CcSEcCtD
Nilotinib—UGT1A1—renal system—nephrolithiasis	0.000975	0.0147	CbGeAlD
Nilotinib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.000951	0.00889	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.000948	0.00886	CcSEcCtD
Nilotinib—Pain in extremity—Hydrochlorothiazide—nephrolithiasis	0.000948	0.00886	CcSEcCtD
Nilotinib—CA12—renal system—nephrolithiasis	0.000943	0.0142	CbGeAlD
Nilotinib—UGT1A1—kidney—nephrolithiasis	0.000942	0.0142	CbGeAlD
Nilotinib—Migraine—Hydrochlorothiazide—nephrolithiasis	0.000933	0.00872	CcSEcCtD
Nilotinib—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.000915	0.00855	CcSEcCtD
Nilotinib—CA12—kidney—nephrolithiasis	0.000911	0.0137	CbGeAlD
Nilotinib—KIT—nephron tubule—nephrolithiasis	0.000898	0.0135	CbGeAlD
Nilotinib—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.000888	0.0083	CcSEcCtD
Nilotinib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.000869	0.00812	CcSEcCtD
Nilotinib—MAP2K5—cortex of kidney—nephrolithiasis	0.000868	0.0131	CbGeAlD
Nilotinib—Abdominal pain upper—Hydrochlorothiazide—nephrolithiasis	0.000865	0.00809	CcSEcCtD
Nilotinib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.000862	0.00806	CcSEcCtD
Nilotinib—Breast disorder—Hydrochlorothiazide—nephrolithiasis	0.000856	0.008	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000853	0.00798	CcSEcCtD
Nilotinib—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.000839	0.00784	CcSEcCtD
Nilotinib—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.000836	0.00781	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.000836	0.00781	CcSEcCtD
Nilotinib—Abdominal distension—Hydrochlorothiazide—nephrolithiasis	0.000824	0.00771	CcSEcCtD
Nilotinib—Influenza—Hydrochlorothiazide—nephrolithiasis	0.000819	0.00766	CcSEcCtD
Nilotinib—KIT—renal system—nephrolithiasis	0.000817	0.0123	CbGeAlD
Nilotinib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.000803	0.00751	CcSEcCtD
Nilotinib—Angina pectoris—Hydrochlorothiazide—nephrolithiasis	0.000798	0.00746	CcSEcCtD
Nilotinib—PDGFRB—renal system—nephrolithiasis	0.000798	0.012	CbGeAlD
Nilotinib—KIT—kidney—nephrolithiasis	0.000789	0.0119	CbGeAlD
Nilotinib—ABL1—nephron tubule—nephrolithiasis	0.000782	0.0118	CbGeAlD
Nilotinib—PDGFRB—kidney—nephrolithiasis	0.000771	0.0116	CbGeAlD
Nilotinib—KIT—cortex of kidney—nephrolithiasis	0.000769	0.0116	CbGeAlD
Nilotinib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.000766	0.00716	CcSEcCtD
Nilotinib—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.000766	0.00716	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.000761	0.00712	CcSEcCtD
Nilotinib—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.000757	0.00707	CcSEcCtD
Nilotinib—Erectile dysfunction—Hydrochlorothiazide—nephrolithiasis	0.000754	0.00705	CcSEcCtD
Nilotinib—PDGFRB—cortex of kidney—nephrolithiasis	0.000751	0.0113	CbGeAlD
Nilotinib—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.000748	0.00699	CcSEcCtD
Nilotinib—CA1—renal system—nephrolithiasis	0.000747	0.0112	CbGeAlD
Nilotinib—Weight increased—Hydrochlorothiazide—nephrolithiasis	0.000745	0.00697	CcSEcCtD
Nilotinib—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.000739	0.00691	CcSEcCtD
Nilotinib—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.000734	0.00687	CcSEcCtD
Nilotinib—CA1—kidney—nephrolithiasis	0.000722	0.0109	CbGeAlD
Nilotinib—Acute coronary syndrome—Hydrochlorothiazide—nephrolithiasis	0.00072	0.00673	CcSEcCtD
Nilotinib—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.000718	0.00671	CcSEcCtD
Nilotinib—Neuropathy peripheral—Hydrochlorothiazide—nephrolithiasis	0.000716	0.00669	CcSEcCtD
Nilotinib—Myocardial infarction—Hydrochlorothiazide—nephrolithiasis	0.000716	0.00669	CcSEcCtD
Nilotinib—Jaundice—Hydrochlorothiazide—nephrolithiasis	0.000712	0.00665	CcSEcCtD
Nilotinib—ABL1—renal system—nephrolithiasis	0.000711	0.0107	CbGeAlD
Nilotinib—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00071	0.00664	CcSEcCtD
Nilotinib—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00071	0.00664	CcSEcCtD
Nilotinib—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.000696	0.00651	CcSEcCtD
Nilotinib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.000689	0.00644	CcSEcCtD
Nilotinib—ABL1—kidney—nephrolithiasis	0.000687	0.0103	CbGeAlD
Nilotinib—ABL1—cortex of kidney—nephrolithiasis	0.000669	0.0101	CbGeAlD
Nilotinib—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.000667	0.00624	CcSEcCtD
Nilotinib—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.000657	0.00614	CcSEcCtD
Nilotinib—Hepatitis—Hydrochlorothiazide—nephrolithiasis	0.000656	0.00613	CcSEcCtD
Nilotinib—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.000652	0.0061	CcSEcCtD
Nilotinib—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.000651	0.00608	CcSEcCtD
Nilotinib—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.000646	0.00604	CcSEcCtD
Nilotinib—CA4—nephron tubule—nephrolithiasis	0.000642	0.00967	CbGeAlD
Nilotinib—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.000632	0.00591	CcSEcCtD
Nilotinib—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00062	0.00579	CcSEcCtD
Nilotinib—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.000611	0.00571	CcSEcCtD
Nilotinib—Flushing—Hydrochlorothiazide—nephrolithiasis	0.000608	0.00569	CcSEcCtD
Nilotinib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.000586	0.00547	CcSEcCtD
Nilotinib—CA4—renal system—nephrolithiasis	0.000584	0.00879	CbGeAlD
Nilotinib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.000579	0.00541	CcSEcCtD
Nilotinib—Erythema—Hydrochlorothiazide—nephrolithiasis	0.000571	0.00533	CcSEcCtD
Nilotinib—CA4—kidney—nephrolithiasis	0.000564	0.0085	CbGeAlD
Nilotinib—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.000562	0.00526	CcSEcCtD
Nilotinib—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.000559	0.00522	CcSEcCtD
Nilotinib—Back pain—Hydrochlorothiazide—nephrolithiasis	0.000552	0.00516	CcSEcCtD
Nilotinib—CA4—cortex of kidney—nephrolithiasis	0.00055	0.00828	CbGeAlD
Nilotinib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.000549	0.00513	CcSEcCtD
Nilotinib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.000538	0.00503	CcSEcCtD
Nilotinib—Tremor—Hydrochlorothiazide—nephrolithiasis	0.000535	0.005	CcSEcCtD
Nilotinib—CA2—nephron tubule—nephrolithiasis	0.000533	0.00802	CbGeAlD
Nilotinib—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.000529	0.00495	CcSEcCtD
Nilotinib—Anaemia—Hydrochlorothiazide—nephrolithiasis	0.000527	0.00493	CcSEcCtD
Nilotinib—Malaise—Hydrochlorothiazide—nephrolithiasis	0.000515	0.00481	CcSEcCtD
Nilotinib—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.000513	0.00479	CcSEcCtD
Nilotinib—Syncope—Hydrochlorothiazide—nephrolithiasis	0.000512	0.00478	CcSEcCtD
Nilotinib—Leukopenia—Hydrochlorothiazide—nephrolithiasis	0.000511	0.00477	CcSEcCtD
Nilotinib—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.000504	0.00471	CcSEcCtD
Nilotinib—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.000502	0.00469	CcSEcCtD
Nilotinib—Cough—Hydrochlorothiazide—nephrolithiasis	0.000498	0.00465	CcSEcCtD
Nilotinib—ABCG2—nephron tubule—nephrolithiasis	0.000493	0.00743	CbGeAlD
Nilotinib—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.000486	0.00454	CcSEcCtD
Nilotinib—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.000486	0.00454	CcSEcCtD
Nilotinib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.000486	0.00454	CcSEcCtD
Nilotinib—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.000484	0.00453	CcSEcCtD
Nilotinib—CA2—renal system—nephrolithiasis	0.000484	0.00729	CbGeAlD
Nilotinib—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00048	0.00449	CcSEcCtD
Nilotinib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.000475	0.00444	CcSEcCtD
Nilotinib—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.00047	0.00439	CcSEcCtD
Nilotinib—CA2—kidney—nephrolithiasis	0.000468	0.00705	CbGeAlD
Nilotinib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.000466	0.00435	CcSEcCtD
Nilotinib—CYP2C8—renal system—nephrolithiasis	0.000461	0.00694	CbGeAlD
Nilotinib—Shock—Hydrochlorothiazide—nephrolithiasis	0.000458	0.00428	CcSEcCtD
Nilotinib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.000456	0.00426	CcSEcCtD
Nilotinib—CA2—cortex of kidney—nephrolithiasis	0.000456	0.00686	CbGeAlD
Nilotinib—CYP2B6—nephron tubule—nephrolithiasis	0.000455	0.00685	CbGeAlD
Nilotinib—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.000455	0.00425	CcSEcCtD
Nilotinib—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00045	0.00421	CcSEcCtD
Nilotinib—CYP2C8—kidney—nephrolithiasis	0.000446	0.00671	CbGeAlD
Nilotinib—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.000444	0.00415	CcSEcCtD
Nilotinib—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.000435	0.00407	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.000424	0.00397	CcSEcCtD
Nilotinib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.000421	0.00394	CcSEcCtD
Nilotinib—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.000418	0.00391	CcSEcCtD
Nilotinib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.000415	0.00388	CcSEcCtD
Nilotinib—CYP2B6—renal system—nephrolithiasis	0.000414	0.00623	CbGeAlD
Nilotinib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00041	0.00383	CcSEcCtD
Nilotinib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.000405	0.00378	CcSEcCtD
Nilotinib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.000402	0.00375	CcSEcCtD
Nilotinib—CYP2B6—kidney—nephrolithiasis	0.0004	0.00602	CbGeAlD
Nilotinib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.000398	0.00372	CcSEcCtD
Nilotinib—Pain—Hydrochlorothiazide—nephrolithiasis	0.000398	0.00372	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.000384	0.00359	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.000381	0.00356	CcSEcCtD
Nilotinib—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00037	0.00346	CcSEcCtD
Nilotinib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.000368	0.00344	CcSEcCtD
Nilotinib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.000368	0.00344	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.000343	0.00321	CcSEcCtD
Nilotinib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.000334	0.00312	CcSEcCtD
Nilotinib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.000329	0.00308	CcSEcCtD
Nilotinib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.000319	0.00298	CcSEcCtD
Nilotinib—CYP3A4—renal system—nephrolithiasis	0.000312	0.0047	CbGeAlD
Nilotinib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.000308	0.00288	CcSEcCtD
Nilotinib—CYP2D6—renal system—nephrolithiasis	0.000307	0.00463	CbGeAlD
Nilotinib—CYP3A4—kidney—nephrolithiasis	0.000302	0.00455	CbGeAlD
Nilotinib—CYP2D6—kidney—nephrolithiasis	0.000297	0.00447	CbGeAlD
Nilotinib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.000296	0.00277	CcSEcCtD
Nilotinib—Rash—Hydrochlorothiazide—nephrolithiasis	0.000294	0.00274	CcSEcCtD
Nilotinib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.000293	0.00274	CcSEcCtD
Nilotinib—Headache—Hydrochlorothiazide—nephrolithiasis	0.000292	0.00273	CcSEcCtD
Nilotinib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.000277	0.00259	CcSEcCtD
Nilotinib—CA3—Metabolism—AGXT—nephrolithiasis	0.000262	0.00554	CbGpPWpGaD
Nilotinib—ABCB1—nephron tubule—nephrolithiasis	0.000243	0.00366	CbGeAlD
Nilotinib—PDGFRA—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000238	0.00503	CbGpPWpGaD
Nilotinib—CA3—Metabolism—SLC26A1—nephrolithiasis	0.000223	0.00471	CbGpPWpGaD
Nilotinib—CA3—Metabolism—APRT—nephrolithiasis	0.000223	0.00471	CbGpPWpGaD
Nilotinib—EPHA2—Direct p53 effectors—SPP1—nephrolithiasis	0.000222	0.00469	CbGpPWpGaD
Nilotinib—ABCB1—renal system—nephrolithiasis	0.000221	0.00333	CbGeAlD
Nilotinib—MAPK8—Toll-like Receptor Signaling Pathway—SPP1—nephrolithiasis	0.000218	0.0046	CbGpPWpGaD
Nilotinib—PDGFRB—Regulation of Actin Cytoskeleton—CHRM3—nephrolithiasis	0.000215	0.00453	CbGpPWpGaD
Nilotinib—ABCB1—kidney—nephrolithiasis	0.000214	0.00322	CbGeAlD
Nilotinib—LYN—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000212	0.00448	CbGpPWpGaD
Nilotinib—ABCB1—cortex of kidney—nephrolithiasis	0.000208	0.00313	CbGeAlD
Nilotinib—MAPK14—FGF signaling pathway—SPP1—nephrolithiasis	0.000206	0.00435	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000201	0.00424	CbGpPWpGaD
Nilotinib—CA14—Metabolism—GRHPR—nephrolithiasis	0.00019	0.00401	CbGpPWpGaD
Nilotinib—CA6—Metabolism—GRHPR—nephrolithiasis	0.000185	0.0039	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—SLC7A9—nephrolithiasis	0.000182	0.00383	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—DGKH—nephrolithiasis	0.000182	0.00383	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000174	0.00367	CbGpPWpGaD
Nilotinib—MAPK11—Toll-like Receptor Signaling Pathway—SPP1—nephrolithiasis	0.000173	0.00366	CbGpPWpGaD
Nilotinib—CA7—Metabolism—GRHPR—nephrolithiasis	0.000173	0.00364	CbGpPWpGaD
Nilotinib—MAPK8—Regulation of toll-like receptor signaling pathway—SPP1—nephrolithiasis	0.00017	0.00359	CbGpPWpGaD
Nilotinib—CYP2B6—Biological oxidations—SLC26A1—nephrolithiasis	0.000169	0.00357	CbGpPWpGaD
Nilotinib—CA14—Metabolism—AGXT—nephrolithiasis	0.000169	0.00357	CbGpPWpGaD
Nilotinib—MAPK8—BDNF signaling pathway—SPP1—nephrolithiasis	0.000165	0.00349	CbGpPWpGaD
Nilotinib—CA6—Metabolism—AGXT—nephrolithiasis	0.000165	0.00348	CbGpPWpGaD
Nilotinib—CA12—Metabolism—GRHPR—nephrolithiasis	0.00016	0.00338	CbGpPWpGaD
Nilotinib—CA3—Metabolism—AQP1—nephrolithiasis	0.000159	0.00336	CbGpPWpGaD
Nilotinib—MAP2K5—BDNF signaling pathway—SPP1—nephrolithiasis	0.000157	0.00332	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AGXT—nephrolithiasis	0.000154	0.00325	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000147	0.0031	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000147	0.0031	CbGpPWpGaD
Nilotinib—HCK—Focal Adhesion—SPP1—nephrolithiasis	0.000146	0.00309	CbGpPWpGaD
Nilotinib—CA14—Metabolism—SLC26A1—nephrolithiasis	0.000144	0.00304	CbGpPWpGaD
Nilotinib—CA14—Metabolism—APRT—nephrolithiasis	0.000144	0.00304	CbGpPWpGaD
Nilotinib—CA3—Metabolism—CHRM3—nephrolithiasis	0.000144	0.00304	CbGpPWpGaD
Nilotinib—CYP2C8—Biological oxidations—SLC26A1—nephrolithiasis	0.000143	0.00302	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AGXT—nephrolithiasis	0.000142	0.00301	CbGpPWpGaD
Nilotinib—CA6—Metabolism—APRT—nephrolithiasis	0.00014	0.00296	CbGpPWpGaD
Nilotinib—CA6—Metabolism—SLC26A1—nephrolithiasis	0.00014	0.00296	CbGpPWpGaD
Nilotinib—MAPK11—Regulation of toll-like receptor signaling pathway—SPP1—nephrolithiasis	0.000135	0.00286	CbGpPWpGaD
Nilotinib—MAPK8—Focal Adhesion—SPP1—nephrolithiasis	0.000132	0.0028	CbGpPWpGaD
Nilotinib—BLK—Focal Adhesion—SPP1—nephrolithiasis	0.000132	0.0028	CbGpPWpGaD
Nilotinib—FGR—Focal Adhesion—SPP1—nephrolithiasis	0.000132	0.00279	CbGpPWpGaD
Nilotinib—CA7—Metabolism—APRT—nephrolithiasis	0.000131	0.00276	CbGpPWpGaD
Nilotinib—CA7—Metabolism—SLC26A1—nephrolithiasis	0.000131	0.00276	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000131	0.00276	CbGpPWpGaD
Nilotinib—CA4—Metabolism—GRHPR—nephrolithiasis	0.000127	0.00269	CbGpPWpGaD
Nilotinib—MAP2K5—Focal Adhesion—SPP1—nephrolithiasis	0.000126	0.00266	CbGpPWpGaD
Nilotinib—MAPK14—Toll-like Receptor Signaling Pathway—SPP1—nephrolithiasis	0.000124	0.00261	CbGpPWpGaD
Nilotinib—CA2—Metabolism—GRHPR—nephrolithiasis	0.000122	0.00258	CbGpPWpGaD
Nilotinib—CA12—Metabolism—SLC26A1—nephrolithiasis	0.000121	0.00256	CbGpPWpGaD
Nilotinib—CA12—Metabolism—APRT—nephrolithiasis	0.000121	0.00256	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.00012	0.00253	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.00012	0.00253	CbGpPWpGaD
Nilotinib—CYP2D6—Biological oxidations—SLC26A1—nephrolithiasis	0.000118	0.00248	CbGpPWpGaD
Nilotinib—CA1—Metabolism—GRHPR—nephrolithiasis	0.000117	0.00248	CbGpPWpGaD
Nilotinib—CYP2C9—Biological oxidations—SLC26A1—nephrolithiasis	0.000117	0.00246	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AGXT—nephrolithiasis	0.000114	0.0024	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—DGKH—nephrolithiasis	0.000109	0.00231	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—SLC7A9—nephrolithiasis	0.000109	0.00231	CbGpPWpGaD
Nilotinib—HCK—Disease—SLC26A1—nephrolithiasis	0.000109	0.00231	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AGXT—nephrolithiasis	0.000109	0.0023	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—SLC7A9—nephrolithiasis	0.000109	0.0023	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—DGKH—nephrolithiasis	0.000109	0.0023	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ADCY10—nephrolithiasis	0.000107	0.00227	CbGpPWpGaD
Nilotinib—BRAF—Focal Adhesion—SPP1—nephrolithiasis	0.000104	0.00221	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AGXT—nephrolithiasis	0.000104	0.00221	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—SLC7A9—nephrolithiasis	0.000104	0.00219	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—DGKH—nephrolithiasis	0.000104	0.00219	CbGpPWpGaD
Nilotinib—CA9—Metabolism—GRHPR—nephrolithiasis	0.000103	0.00218	CbGpPWpGaD
Nilotinib—CA14—Metabolism—AQP1—nephrolithiasis	0.000102	0.00216	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ADCY10—nephrolithiasis	0.000102	0.00216	CbGpPWpGaD
Nilotinib—CA6—Metabolism—AQP1—nephrolithiasis	9.98e-05	0.00211	CbGpPWpGaD
Nilotinib—KIT—Signaling by PDGF—SPP1—nephrolithiasis	9.84e-05	0.00208	CbGpPWpGaD
Nilotinib—HCK—Disease—ATP6V0A4—nephrolithiasis	9.73e-05	0.00206	CbGpPWpGaD
Nilotinib—MAPK14—Regulation of toll-like receptor signaling pathway—SPP1—nephrolithiasis	9.66e-05	0.00204	CbGpPWpGaD
Nilotinib—CA4—Metabolism—APRT—nephrolithiasis	9.66e-05	0.00204	CbGpPWpGaD
Nilotinib—CA4—Metabolism—SLC26A1—nephrolithiasis	9.66e-05	0.00204	CbGpPWpGaD
Nilotinib—MAPK14—BDNF signaling pathway—SPP1—nephrolithiasis	9.4e-05	0.00198	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AQP1—nephrolithiasis	9.32e-05	0.00197	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by PDGF—SPP1—nephrolithiasis	9.32e-05	0.00197	CbGpPWpGaD
Nilotinib—CA2—Metabolism—SLC26A1—nephrolithiasis	9.26e-05	0.00196	CbGpPWpGaD
Nilotinib—CA14—Metabolism—CHRM3—nephrolithiasis	9.26e-05	0.00196	CbGpPWpGaD
Nilotinib—CA2—Metabolism—APRT—nephrolithiasis	9.26e-05	0.00196	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AGXT—nephrolithiasis	9.18e-05	0.00194	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—RGS14—nephrolithiasis	9.14e-05	0.00193	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	9.06e-05	0.00191	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	9.06e-05	0.00191	CbGpPWpGaD
Nilotinib—CA6—Metabolism—CHRM3—nephrolithiasis	9.03e-05	0.00191	CbGpPWpGaD
Nilotinib—PDGFRA—Focal Adhesion—SPP1—nephrolithiasis	9e-05	0.0019	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—SLC7A9—nephrolithiasis	8.95e-05	0.00189	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—DGKH—nephrolithiasis	8.95e-05	0.00189	CbGpPWpGaD
Nilotinib—CA1—Metabolism—SLC26A1—nephrolithiasis	8.88e-05	0.00188	CbGpPWpGaD
Nilotinib—CA1—Metabolism—APRT—nephrolithiasis	8.88e-05	0.00188	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—RGS14—nephrolithiasis	8.69e-05	0.00184	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AQP1—nephrolithiasis	8.63e-05	0.00182	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ADCY10—nephrolithiasis	8.57e-05	0.00181	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ADCY10—nephrolithiasis	8.48e-05	0.00179	CbGpPWpGaD
Nilotinib—CA7—Metabolism—CHRM3—nephrolithiasis	8.43e-05	0.00178	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	8.42e-05	0.00178	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	8.42e-05	0.00178	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by PDGF—SPP1—nephrolithiasis	8.39e-05	0.00177	CbGpPWpGaD
Nilotinib—PDGFRB—Focal Adhesion—SPP1—nephrolithiasis	8.11e-05	0.00171	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	7.93e-05	0.00168	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	7.93e-05	0.00168	CbGpPWpGaD
Nilotinib—BRAF—Disease—SLC26A1—nephrolithiasis	7.81e-05	0.00165	CbGpPWpGaD
Nilotinib—CA9—Metabolism—APRT—nephrolithiasis	7.81e-05	0.00165	CbGpPWpGaD
Nilotinib—CA9—Metabolism—SLC26A1—nephrolithiasis	7.81e-05	0.00165	CbGpPWpGaD
Nilotinib—CA12—Metabolism—CHRM3—nephrolithiasis	7.81e-05	0.00165	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ADCY10—nephrolithiasis	7.72e-05	0.00163	CbGpPWpGaD
Nilotinib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	7.69e-05	0.00162	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	7.51e-05	0.00159	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	7.51e-05	0.00159	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ADCY10—nephrolithiasis	7.31e-05	0.00154	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—RGS14—nephrolithiasis	7.28e-05	0.00154	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—RGS14—nephrolithiasis	7.21e-05	0.00152	CbGpPWpGaD
Nilotinib—KIT—Disease—SLC26A1—nephrolithiasis	7.11e-05	0.0015	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	7.07e-05	0.00149	CbGpPWpGaD
Nilotinib—BRAF—Disease—ATP6V0A4—nephrolithiasis	6.96e-05	0.00147	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AQP1—nephrolithiasis	6.88e-05	0.00145	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—SPP1—nephrolithiasis	6.74e-05	0.00142	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—SLC26A1—nephrolithiasis	6.73e-05	0.00142	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AQP1—nephrolithiasis	6.6e-05	0.00139	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ADCY10—nephrolithiasis	6.59e-05	0.00139	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—RGS14—nephrolithiasis	6.57e-05	0.00139	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	6.47e-05	0.00137	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	6.47e-05	0.00137	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ADCY10—nephrolithiasis	6.45e-05	0.00136	CbGpPWpGaD
Nilotinib—KIT—Disease—ATP6V0A4—nephrolithiasis	6.33e-05	0.00134	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AQP1—nephrolithiasis	6.33e-05	0.00134	CbGpPWpGaD
Nilotinib—CA4—Metabolism—CHRM3—nephrolithiasis	6.23e-05	0.00132	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—RGS14—nephrolithiasis	6.22e-05	0.00131	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—DGKH—nephrolithiasis	6.17e-05	0.0013	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ATP6V0A4—nephrolithiasis	6.17e-05	0.0013	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—GRHPR—nephrolithiasis	6.14e-05	0.0013	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ADCY10—nephrolithiasis	6.11e-05	0.00129	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—SLC26A1—nephrolithiasis	6.06e-05	0.00128	CbGpPWpGaD
Nilotinib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	6e-05	0.00127	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ATP6V0A4—nephrolithiasis	6e-05	0.00127	CbGpPWpGaD
Nilotinib—CA2—Metabolism—CHRM3—nephrolithiasis	5.97e-05	0.00126	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ATP6V0A4—nephrolithiasis	5.87e-05	0.00124	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—DGKH—nephrolithiasis	5.87e-05	0.00124	CbGpPWpGaD
Nilotinib—CA1—Metabolism—CHRM3—nephrolithiasis	5.72e-05	0.00121	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RGS14—nephrolithiasis	5.6e-05	0.00118	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AQP1—nephrolithiasis	5.56e-05	0.00118	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RGS14—nephrolithiasis	5.48e-05	0.00116	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AGXT—nephrolithiasis	5.47e-05	0.00116	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ATP6V0A4—nephrolithiasis	5.4e-05	0.00114	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ADCY10—nephrolithiasis	5.29e-05	0.00112	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—GRHPR—nephrolithiasis	5.21e-05	0.0011	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RGS14—nephrolithiasis	5.2e-05	0.0011	CbGpPWpGaD
Nilotinib—CA9—Metabolism—CHRM3—nephrolithiasis	5.03e-05	0.00106	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.92e-05	0.00104	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—DGKH—nephrolithiasis	4.92e-05	0.00104	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	4.9e-05	0.00103	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	4.9e-05	0.00103	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.87e-05	0.00103	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—DGKH—nephrolithiasis	4.87e-05	0.00103	CbGpPWpGaD
Nilotinib—LCK—Disease—SLC26A1—nephrolithiasis	4.86e-05	0.00103	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APRT—nephrolithiasis	4.65e-05	0.000982	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—SLC26A1—nephrolithiasis	4.65e-05	0.000982	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AGXT—nephrolithiasis	4.64e-05	0.00098	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	4.55e-05	0.000962	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	4.55e-05	0.000962	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RGS14—nephrolithiasis	4.49e-05	0.000949	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CHRM3—nephrolithiasis	4.46e-05	0.000943	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—DGKH—nephrolithiasis	4.44e-05	0.000937	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.44e-05	0.000937	CbGpPWpGaD
Nilotinib—LCK—Disease—ATP6V0A4—nephrolithiasis	4.34e-05	0.000916	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CHRM3—nephrolithiasis	4.24e-05	0.000896	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—DGKH—nephrolithiasis	4.2e-05	0.000887	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ATP6V0A4—nephrolithiasis	4.2e-05	0.000887	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PTH—nephrolithiasis	4.08e-05	0.000862	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	4.06e-05	0.000857	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	4.06e-05	0.000857	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APRT—nephrolithiasis	3.95e-05	0.000833	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	3.95e-05	0.000833	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PTH—nephrolithiasis	3.88e-05	0.00082	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—GRHPR—nephrolithiasis	3.82e-05	0.000806	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.78e-05	0.000799	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—DGKH—nephrolithiasis	3.78e-05	0.000799	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.7e-05	0.000782	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—DGKH—nephrolithiasis	3.7e-05	0.000782	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CHRM3—nephrolithiasis	3.56e-05	0.000751	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CHRM3—nephrolithiasis	3.52e-05	0.000744	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.51e-05	0.000742	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—DGKH—nephrolithiasis	3.51e-05	0.000742	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AGXT—nephrolithiasis	3.4e-05	0.000718	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AQP1—nephrolithiasis	3.31e-05	0.0007	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTH—nephrolithiasis	3.25e-05	0.000687	CbGpPWpGaD
Nilotinib—ABCB1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	3.25e-05	0.000685	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—GRHPR—nephrolithiasis	3.23e-05	0.000682	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTH—nephrolithiasis	3.22e-05	0.000681	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CHRM3—nephrolithiasis	3.21e-05	0.000677	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CHRM3—nephrolithiasis	3.04e-05	0.000641	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—DGKH—nephrolithiasis	3.04e-05	0.000641	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ATP6V0A4—nephrolithiasis	3.04e-05	0.000641	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—CHRM3—nephrolithiasis	3e-05	0.000633	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTH—nephrolithiasis	2.93e-05	0.00062	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—SLC26A1—nephrolithiasis	2.89e-05	0.000611	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APRT—nephrolithiasis	2.89e-05	0.000611	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AGXT—nephrolithiasis	2.88e-05	0.000608	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GRHPR—nephrolithiasis	2.82e-05	0.000595	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AQP1—nephrolithiasis	2.81e-05	0.000594	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTH—nephrolithiasis	2.78e-05	0.000586	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CHRM3—nephrolithiasis	2.73e-05	0.000578	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CHRM3—nephrolithiasis	2.68e-05	0.000566	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GRHPR—nephrolithiasis	2.65e-05	0.00056	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GRHPR—nephrolithiasis	2.63e-05	0.000555	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CHRM3—nephrolithiasis	2.54e-05	0.000537	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CHRM3—nephrolithiasis	2.54e-05	0.000536	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AGXT—nephrolithiasis	2.51e-05	0.00053	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTH—nephrolithiasis	2.5e-05	0.000528	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTH—nephrolithiasis	2.45e-05	0.000517	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APRT—nephrolithiasis	2.45e-05	0.000517	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—SLC26A1—nephrolithiasis	2.45e-05	0.000517	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AGXT—nephrolithiasis	2.36e-05	0.000499	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AGXT—nephrolithiasis	2.34e-05	0.000495	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTH—nephrolithiasis	2.32e-05	0.00049	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CHRM3—nephrolithiasis	2.19e-05	0.000464	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APRT—nephrolithiasis	2.13e-05	0.000451	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—SLC26A1—nephrolithiasis	2.13e-05	0.000451	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AQP1—nephrolithiasis	2.06e-05	0.000435	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—SPP1—nephrolithiasis	2.05e-05	0.000433	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—SLC26A1—nephrolithiasis	2.01e-05	0.000425	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APRT—nephrolithiasis	2.01e-05	0.000425	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTH—nephrolithiasis	2.01e-05	0.000424	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APRT—nephrolithiasis	1.99e-05	0.000421	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—SLC26A1—nephrolithiasis	1.99e-05	0.000421	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—SPP1—nephrolithiasis	1.95e-05	0.000412	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CHRM3—nephrolithiasis	1.86e-05	0.000394	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AQP1—nephrolithiasis	1.74e-05	0.000369	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	1.73e-05	0.000366	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—SPP1—nephrolithiasis	1.63e-05	0.000345	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—SPP1—nephrolithiasis	1.62e-05	0.000342	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CHRM3—nephrolithiasis	1.58e-05	0.000333	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AGXT—nephrolithiasis	1.55e-05	0.000326	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AQP1—nephrolithiasis	1.52e-05	0.000321	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—SPP1—nephrolithiasis	1.47e-05	0.000311	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AQP1—nephrolithiasis	1.43e-05	0.000303	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AQP1—nephrolithiasis	1.42e-05	0.0003	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—SPP1—nephrolithiasis	1.39e-05	0.000294	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CHRM3—nephrolithiasis	1.37e-05	0.00029	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	1.31e-05	0.000278	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APRT—nephrolithiasis	1.31e-05	0.000278	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CHRM3—nephrolithiasis	1.3e-05	0.000274	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CHRM3—nephrolithiasis	1.28e-05	0.000271	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SPP1—nephrolithiasis	1.26e-05	0.000265	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SPP1—nephrolithiasis	1.23e-05	0.00026	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SPP1—nephrolithiasis	1.17e-05	0.000246	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SPP1—nephrolithiasis	1.01e-05	0.000213	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AQP1—nephrolithiasis	9.37e-06	0.000198	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	8.47e-06	0.000179	CbGpPWpGaD
